Triple Negative Breast Cancer Foundation

Last updated
Triple Negative Breast Cancer Foundation
Company type Non-Profit
Founded2006 in Norwood, New Jersey
Headquarters
Norwood   OOjs UI icon edit-ltr-progressive.svg
,
United States  OOjs UI icon edit-ltr-progressive.svg
Key people
Hayley Dinerman (Co-founder & Executive Director)
Board of Trustees
Ann Arnold
Allison Axenrod
Melissa Berry
Drew Cawthorne
Ricki Fairley
Ogori Kalu, MD
Rita Nanda, MD
Jennifer K. Sweetwood
Bryan Tucker
Eric P. Winer, MD
Robin Woolcock
Scientific Advisory Board
Lisa A. Carey, MD, UNC Lineberger Comprehensive Cancer Center
Susan M. Domchek, MD
Lisa A. Newman, MD, Weill Cornell Medicine
George W. Sledge, Jr., MD, Stanford University Medical Center
Eric P. Winer, MD, Yale Cancer Center
Global Ambassadors
Robin Woolcock, UK Ambassador
Website tnbcfoundation.org

The Triple Negative Breast Cancer Foundation ("TNBC Foundation") is a nonprofit organization dedicated to raising awareness of triple negative breast cancer. The foundation supports scientists and researchers in their efforts to determine the definitive causes of triple negative breast cancer so that effective detection, diagnosis, prevention, and treatment can be pursued and achieved.

Contents

Since its inception in 2006, TNBC Foundation has raised over $15 million to further this mission. [1]

History

TNBC Foundation was founded in 2006 in honor of Nancy Block-Zenna, who, at age 35, was diagnosed with triple negative breast cancer. In response to her diagnosis, her close friends launched the TNBC Foundation to raise awareness and support research for this particular type of breast cancer. [2] Block-Zenna died of the disease in 2007, 212 years after her diagnosis. [2] At the time, little was known about triple negative breast cancer, and research efforts were minimal. The Foundation was created to raise awareness about TNBC, provide credible information about the disease, fund TNBC-specific research, and create a caring community of support for Thrivers and their families.

Grants and Awards

TNBC Foundation helps set research agendas around the disease, ensuring that triple negative breast cancer research is never neglected. The Foundation’s research investments have had an exponential impact. An initial $1 million investment with the American Association of Cancer Research has generated $17.6 million in additional TNBC research.

In 2008, the Triple Negative Breast Cancer Foundation co-funded a research grant with the Susan G. Komen for the Cure Foundation. TNBC Foundation's initial $500,000 contribution marks the first time a nonprofit partner has co-funded one of Komen's "Promise Grants". Worth $7.5 million over five years, Promise Grants are designed to bring clinical researchers and basic scientists together to deliver new treatments for patients as quickly as possible. The Promise Grant was awarded to Dr. Andreas Forero of the University of Alabama at Birmingham Comprehensive Cancer Center. Forero and his team are researching a new targeted therapy for triple negative breast cancer.

Along with the American Association for Cancer Research, the Triple Negative Breast Cancer Foundation awarded the AACR-Triple Negative Breast Cancer Foundation Career Development Award for Clinical/Translational Research to Eddy Yang, MD, PhD in 2015. [3] This three-year, $250,000 award contributed scientific advancements, including utilizing inhibitors of DNA repair to induce cancer vulnerability to PARP inhibitors. [4]

In 2023, the Triple Negative Breast Cancer Foundation partnered with the ASCO Foundation to award Ana Garrido-Castro, MD, with the 2023 Conquer Cancer -Triple Negative Breast Cancer Foundation Advanced Clinical Research Award. [5] This three-year, $450,000 grant supports mid-career physician scientists who wish to conduct original and currently unfunded research that supports the discovery of new targeted treatments for patients with triple negative breast cancer.

You can find updates on all of the TNBC Foundation’s research investments on their website.

Global Activities

In 2021, TNBC Foundation Board Member Robin Woolcock started the UK Charity for Triple Negative Breast Cancer. The UK Charity for TNBC is a registered charity dedicated to helping people affected by triple negative breast cancer by providing access to easy-to-understand and reliable information. They also ensure that the voice of those with TNBC is heard and that their specific needs are recognized and addressed. [6]

Events

TNBC Foundation founded and hosts TNBC Day, the only global event dedicated to raising awareness and funding TNBC-specific research every March. In 2024 they partnered with Carrabba’s Italian Grill, where $35,000 was raised for TNBC research with Trios for a Cure. [7]

TNBC Foundation hosts multiple events throughout the year to raise funds for TNBC-specific research, including Concert for a Cure, an event benefitting the TNBC Foundation. [8] They also host No One Fights Alone, an annual gala and awards ceremony to honor giants in the field of TNBC research, as well as companies and individuals who have made significant impact on the TNBC community. Over the years, TNBC Foundation has raised more than $4 million through their gala to support vital research, resources, programs, and services for the TNBC community. [9]

For their community members, the TNBC Foundation hosts monthly virtual meetups including Tuesdays with TNBC Friends, Metastatic Mondays with TNBC Friends, and Thursdays with TNBC Friends. These free online forums allow members of the TNBC community to connect, share information, exchange treatment tips, and support each other during a participant-led discussion. [10]

Symposium

On December 11, 2007, the TNBC Foundation and Susan G. Komen for the Cure convened one of the first "think tanks" dedicated specifically to triple negative breast cancer. The meeting was held prior to the opening of the annual San Antonio Breast Cancer Symposium. [11]

Thirty researchers, from leading cancer institutions in North America and Europe, were invited to share information on the latest science, to discuss potential research collaborations and develop a scientific agenda for future research and clinical trials to find effective treatment for women with this subtype of breast cancer. The meeting also marked the first joint effort between TNBCF and Susan G. Komen for the Cure to share resources to accelerate research and progress for women who are not benefiting from recent advances in breast cancer research. [11]

The goal of the meeting was to create the first comprehensive publication and white-paper summarizing the "state of the science" with input and authorship from leading researchers from around the world who have been dedicated specifically to this subtype of the disease. The publication will also include a roadmap and recommendations for planning, funding and designing the next level of research with the goal of identifying effective, tailored therapies for these women, thereby further reducing the rates of breast cancer mortality around the world. [12]

Co-chairing the symposium were Allison Axenrod, executive director of TNBCF, and Hayley Dinerman, TNBCF's director of operations. The program was planned by TNBC's medical advisory board, which includes Dr. Winer as well as Lisa A. Carey, medical director of the University of North Carolina Lineberger Comprehensive Cancer Center, and George W. Sledge, Jr., professor of Medicine and Pathology and co-chair of the Breast Cancer Program at the Indiana University School of Medicine. [12] [13] [14]

TNBC has convened the Symposium each year since 2007. In 2010, over 30 researchers and scientists attended the Symposium, which was again co-sponsored by Susan G. Komen for the Cure and the Breast Cancer Research Foundation (BCRF). That year, the TNBCF awarded its first independent grants to two researchers who were doing research in the area of triple negative breast cancer.

Related Research Articles

Inflammatory breast cancer (IBC) is one of the most aggressive types of breast cancer. It can occur in women of any age. It is referred to as "inflammatory" due to its frequent presentation with symptoms resembling a skin inflammation, such as erysipelas.

<span class="mw-page-title-main">Susan G. Komen 3-Day for the Cure</span>

The Susan G. Komen 3-Day, frequently referred to as the 3-Day, is a 60-mile walk to raise funds for Susan G. Komen for the Cure and promote awareness to fight breast cancer. Individual participants must raise at least $2,300 to walk 60 miles (96 km) over a three-day weekend.

<span class="mw-page-title-main">Susan G. Komen for the Cure</span> American non-profit organization

Susan G. Komen is a breast cancer organization in the United States.

The American Association for Cancer Research (AACR) is the world's oldest and largest professional association related to cancer research. Based in Philadelphia, the AACR focuses on all aspects of cancer research, including basic, clinical, and translational research into the etiology, prevention, diagnosis, and treatment of cancer. Founded in 1907 by 11 physicians and scientists, the organization now has more than 58,000 members in 142 countries and territories. The mission of the AACR is to prevent and cure cancer through research, education, communication, collaboration, science policy and advocacy, and funding for cancer research.

<span class="mw-page-title-main">Nancy Brinker</span> Non-profit executive and political appointee

Nancy Goodman Brinker is the founder of The Promise Fund and Susan G. Komen for the Cure. Brinker was also United States Ambassador to Hungary from 2001 to 2003 and Chief of Protocol of the United States from 2007 to the end of the George W. Bush administration. In 2011, she was appointed a Goodwill Ambassador for Cancer Control by the World Health Organization.

<span class="mw-page-title-main">Richard Pestell</span> Australian oncologist and endocrinologist

Richard G. Pestell is an Australian American oncologist, endocrinologist and research scientist. Pestell was appointed an Officer of the Order of Australia for distinguished service to medicine and medical education in 2019 by Queen Elizabeth II. He was previously Executive Vice President of Thomas Jefferson University and Director of the Sidney Kimmel Cancer Center of Thomas Jefferson University. He founded six biotechnology companies developing cancer therapy and diagnostics. He is currently Distinguished Professor, Translational Medical Research, and the President of the Pennsylvania Cancer and Regenerative Medicine Research Center at the Baruch S. Blumberg Institute.

The Komen Brinker Award for Scientific Distinction was established by Susan G. Komen for the Cure in 1992 to recognize leading scientists for their significant work in advancing research concepts or clinical application in the fields of breast cancer research, screening or treatment.

<span class="mw-page-title-main">Breast Cancer Awareness Month</span> Annual health campaign

Breast Cancer Awareness Month (BCAM), also referred to in the United States as National Breast Cancer Awareness Month (NBCAM), is an annual international health campaign organized by major breast cancer charities every October to increase awareness of the disease and raise funds for research into its cause, prevention, diagnosis, treatment, and cure.

Triple-negative breast cancer (TNBC) is any breast cancer that either lacks or shows low levels of estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER2) overexpression and/or gene amplification. Triple-negative is sometimes used as a surrogate term for basal-like.

<span class="mw-page-title-main">Breast cancer research stamp</span>

The breast cancer research stamp (BCRS) is a semi-postal non-denominated postage stamp issued by the United States Postal Service, priced in 2011 as eleven cents higher than the standard first-class letter rate. The surplus above the price of the first-class stamp is collected by the United States Postal Service (USPS) and allocated to the National Institutes of Health (NIH) and the Department of Defense (DoD) for breast cancer research.

<span class="mw-page-title-main">Living Beyond Breast Cancer</span> American nonprofit organization

Living Beyond Breast Cancer (LBBC), is a national 501(c)(3) nonprofit organization headquartered in Bala Cynwyd, just outside Philadelphia, Pennsylvania, in the United States. LBBC works with women who have been diagnosed with breast cancer and their caregivers throughout their experience of diagnosis, treatment and recovery. Their goal to be a "high-touch organization" that provides people with information and support of relevance to their personal experience of breast cancer. The organization supports studies of health care that are sensitive to issues of ethnicity, age, sexual orientation, and diagnosis.

Leronlimab is a humanized monoclonal antibody targeted against the CCR5 receptor found on T lymphocytes of the human immune system. It is being investigated as a potential therapy in the treatment of COVID-19, triple negative breast cancer, and HIV infection. The United States Food and Drug Administration has designated PRO 140 for fast-track approval. In February 2008, the drug entered Phase 2 clinical trials and a phase 3 trial was begun in 2015. In February 2018, Cytodyn Inc reported that the primary endpoint had been achieved in the PRO 140 pivotal combination therapy trial in HIV infection. In 2020 CytoDyn submitted a fast-track biologics license application for treatment of CCR5-tropic HIV-1 Infection.

<span class="mw-page-title-main">Breast Cancer Research Foundation</span> Research organization

The Breast Cancer Research Foundation (BCRF) is an independent, not-for-profit organization which has raised $569.4 million to support clinical and translational research on breast cancer at medical institutions in the United States and abroad. BCRF currently funds over 255 researchers in 14 countries.

<span class="mw-page-title-main">Team Heather</span>

Team Heather is a fundraising group in the Susan G. Komen for the Cure Global Race for the Cure in Washington, D.C., which has raised over $403,000, since June, 2001, for Susan G. Komen for the Cure and breast cancer research, education, screening, and treatment. Team Heather was formed in 2001 to support 25-year-old Heather Gardner (Starcher) (1976–2002), as she began her fight against breast cancer – a fight that ended on September 29, 2002.

Glembatumumab vedotin is an antibody-drug conjugate (ADC) that targets cancer cells expressing transmembrane glycoprotein NMB (GPNMB).

Eric P. Winer is a medical oncologist and clinical researcher specializing in breast cancer. He is director of Yale Cancer Center and president and physician-in-chief of Smilow Cancer Hospital Yale New Haven Health System, effective February 1, 2022. He also is Deputy Dean for Cancer Research at Yale School of Medicine. From 1997 to 2021, he was the Chief of the Breast Oncology Program at Dana–Farber Cancer Institute in Boston, Massachusetts. Beginning in 2013, he held a range of institutional roles at Dana-Farber, including Chief of Clinical Development, the Thompson Chair in Breast Cancer Research and Director of the Dana-Farber/Harvard SPORE in Breast Cancer. He also served as a Professor of Medicine at Harvard Medical School. He was president of the American Society of Clinical Oncology (ASCO) 2022-2023 and became Chair of the Board in mid-June 2023. His career has been focused on breast cancer treatment and research.

<span class="mw-page-title-main">Pinkwashing (breast cancer)</span> Form of cause marketing that uses a range of pink ribbon logos

Pinkwashing is a form of cause marketing that uses a pink ribbon logos. The companies display the pink ribbon logo on products that are known to cause different types of cancer. The Pink ribbon logo symbolizes support for breast cancer-related charities or foundations.

<span class="mw-page-title-main">Atezolizumab</span> Monoclonal anti-PD-L1 antibody

Atezolizumab, sold under the brand name Tecentriq among others, is a monoclonal antibody medication used to treat urothelial carcinoma, non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), hepatocellular carcinoma and alveolar soft part sarcoma, but discontinued for use in triple-negative breast cancer (TNBC). It is a fully humanized, engineered monoclonal antibody of IgG1 isotype against the protein programmed cell death-ligand 1 (PD-L1).

<span class="mw-page-title-main">Sacituzumab govitecan</span> Antibody-drug conjugate

Sacituzumab govitecan, sold under the brand name Trodelvy by Gilead Sciences, is a Trop-2-directed antibody and topoisomerase inhibitor drug conjugate used for the treatment of metastatic triple-negative breast cancer and metastatic urothelial cancer.

<span class="mw-page-title-main">Katherine A. Hoadley</span> American breast cancer researcher

Katherine A. Hoadley is an American breast cancer researcher. As of 2017, she has served as the Associate Director of Cancer Genomics for the High-Throughput Sequencing Facility at UNC Lineberger Comprehensive Cancer Center. Her research is focused on understanding the biology of cancer through gene expression analyses and integrative genomic approaches.

References

  1. "Financial Documents". Triple Negative Breast Cancer Foundation. Retrieved 2024-08-21.
  2. 1 2 "Our Story". Triple Negative Breast Cancer Foundation. Retrieved 2024-08-21.
  3. "Eddy Yang: Doubling Down against Triple Negative Breast Cancer". American Association for Cancer Research (AACR). Retrieved 2024-08-21.
  4. "American Association for Cancer Research and the Triple Negative Breast Cancer Foundation Partner to Offer New Grant Opportunity" (PDF). 2015-01-26.
  5. "Conquer Cancer announces 2023 Advanced Clinical Research Award in Triple Negative Breast Cancer Research Recipient | Conquer Cancer, the ASCO Foundation". www.conquer.org. Retrieved 2024-08-21.
  6. "UK Charity For TNBC". UK Charity For TNBC. 2024-08-21. Retrieved 2024-08-21.
  7. "Carrabba's Italian Grill Raises $35,000 for Triple Negative Breast Cancer Foundation". TAPinto. Retrieved 2024-08-21.
  8. "Our Events". Triple Negative Breast Cancer Foundation. 2025-03-28. Retrieved 2024-08-21.
  9. "No One Fights Alone 2024". Triple Negative Breast Cancer Foundation. 2024-05-22. Retrieved 2024-08-21.
  10. "Home". Triple Negative Breast Cancer Foundation. Retrieved 2024-08-21.
  11. 1 2 "Researchers From Around the World Gather to Discuss Triple Negative Breast Cancer". Reuters. December 13, 2007. Archived from the original on October 6, 2009.
  12. 1 2 Susan G. Komen for the Cure Archived 2008-02-17 at the Wayback Machine
  13. Researchers From Around the World Gather to Discuss Triple Negative Breast Cancer | Reuters
  14. Triple Negative Breast Cancer Foundation Archived 2008-02-28 at the Wayback Machine